US Family Health Plan Prior Authorization Request Form for anakinra (Kineret)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 617-562-5296

OR

The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Step	Please complete patient and physician information	(please print):			
1	Patient Name:	Physician Name:			
	Address:	Address:			
	Sponsor ID #	Phone #:			
04	Date of Birth:	Secure Fax #:			
Step 2	Please complete the clinical assessment:				
	 Is this a pediatric patient (less than 18 years old) with a diagnosis of Neonatal Onset Multisystem Inflammatory Disease (NOMID), Cryopyrin-Associate Periodic Syndrome (CAPS) or systemic juvenile idiopathic arthritis (sJIA)? 	proceed to question 8	□ No proceed to question 2		
	2. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	□ Yes	□ No		
		proceed to question 3	proceed to question 5		
	3. Has the patient had an inadequate response to Humira?	□ Yes	□ No		
		proceed to question 6	proceed to question 4		
	4. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	□ Yes	□ No		
		proceed to question 6	STOP Coverage not approved		
	5. Does the patient have a contraindication to Humira (adalimumab)?	□ Yes	□ No		
		Proceed to question 6	STOP Coverage not approved		
	6. Is this an adult patient (18 years of age or older) with a diagnosis of moderate to severe active rheumatoid arthritis?	a □ Yes	□ No		
		Proceed to question 7	STOP Coverage not approved		
	7. Has the patient failed 1 or more disease modifying antirheumatic drugs (DMARDs)?	□ Yes	□ No		
		Proceed to question 8	STOP Coverage not approved		

8.	Does the patient have a negative TB test result in the past 12 months (or is TB adequately managed)?	☐ Yes proceed to question 9	□ No STOP Coverage not approved
9.	Will the patient be receiving other targeted immunomodulatory biologics with Kineret, including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Olumiant, Orencia, Otezla, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz, Tremfya or Xeljanz/Xeljanz XR?	☐ Yes STOP Coverage not approved	□ No Sign and date below

anakinra (Kineret) Page 2

Prescriber Signature Date [24 April 2019]